Tests rezatapopt in advanced solid tumors with a TP53 Y220C mutation
Tests rezatapopt, alone or with pembrolizumab, in people with advanced TP53 Y220C tumors.
Plain-language title generated from the registry record
Registry title: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Key facts
- Where
- Augsburg, Essen, Frankfurt am Main, Hamburg, and Heidelberg, GermanySee the 5 sites
- Phase
- Phase 1/2
Where in Germany
- Universitätsklinikum AugsburgAugsburg, GermanyTaking people
- Universitätsklinikum EssenEssen, GermanyTaking people
- Universitätsklinikum FrankfurtFrankfurt am Main, GermanyNo longer taking part
- Asklepios Klinik AltonaHamburg, GermanyTaking people
- Nationale Centrum für Tumorerkrankungen (NCT) HeidelbergHeidelberg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- PMV Pharmaceuticals, Inc
- Trial code
- NCT04585750
- Record updated
- 2 October 2026
- Original description
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.Read full original descriptionShow less
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.
Inclusion: At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval; Locally advanced or metastatic solid malignancy with a TP53 Y220C mutation; Eastern Cooperative Oncology Group (ECOG) status of 0 or 1; Previously treated with one or more lines of anticancer therapy and progressive disease; Adequate organ function; Measurable disease per RECIST v1.1 (Phase 2); Additional Criteria for Inclusion in Phase 1b (rezatapopt) + pembrolizumab combination); Anti-PD-1/PD-L1 naive or must have progressed on treatment; Measurable disease.
Exclusion: Anti-cancer therapy within 21 days (or 5 half-lives) of receiving the study drug; Radiotherapy within 14 days of receiving the study drug; Brain metastases, unless neurologically stable and do not require steroids to treat associated neurological symptoms; Stroke or transient ischemic attack within 6 months prior to screening; Strong CYP3A4 inducers and strong CYP2C9 inhibitors/inducers within 14 days of first dose of rezatapopt; History of prior organ transplant; Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and discontinued from that treatment due to a Grade 3 or higher immune-related AE (irAE); Received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention; Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy within 7 days prior to the first dose of study drug; Has previously received rezatapopt; History of leptomeningeal disease or spinal cord compression; History of gastrointestinal (GI) disease that may interfere with absorption of study drug or patients unable to take oral medication; Known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer; Known, active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection; Additional Criteria for Exclusion from Phase 2 (rezatapopt monotherapy); Known KRAS mutation, defined as a single nucleotide variant (SNV) (Phase 2). Exception: Ovarian cancer patients with a known KRAS SNV are permitted; Additional Criteria for Exclusion from Phase 1b (rezatapopt) + pembrolizumab combination); Hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients; Active autoimmune disease that has required systemic treatment in past 2 years; History of radiation pneumonitis; History of (non-infectious) or active pneumonitis / interstitial lung disease that required steroids; Active infection requiring systemic therapy; Known history of HIV infection; Heart conditions such as unstable angina within 6 months prior to screening, uncontrolled hypertension, a heart attack within 6 months prior to screening, congestive heart failure, prolongation of QT interval, or other rhythm abnormalities; Primary CNS tumor.